Cross Country Healthcare, Inc.

NasdaqGS:CCRN Stock Report

Market Cap: US$503.5m

Cross Country Healthcare Future Growth

Future criteria checks 0/6

Cross Country Healthcare's revenue and earnings are forecast to decline at 9% and 3.6% per annum respectively. EPS is expected to decline by 7.6% per annum. Return on equity is forecast to be 4.7% in 3 years.

Key information

-3.6%

Earnings growth rate

-7.6%

EPS growth rate

Healthcare earnings growth17.1%
Revenue growth rate-9.0%
Future return on equity4.7%
Analyst coverage

Good

Last updated04 Jun 2024

Recent future growth updates

Recent updates

Benign Growth For Cross Country Healthcare, Inc. (NASDAQ:CCRN) Underpins Stock's 25% Plummet

Feb 22
Benign Growth For Cross Country Healthcare, Inc. (NASDAQ:CCRN) Underpins Stock's 25% Plummet

Calculating The Intrinsic Value Of Cross Country Healthcare, Inc. (NASDAQ:CCRN)

Feb 09
Calculating The Intrinsic Value Of Cross Country Healthcare, Inc. (NASDAQ:CCRN)

Cross Country Healthcare (NASDAQ:CCRN) Is Achieving High Returns On Its Capital

Oct 09
Cross Country Healthcare (NASDAQ:CCRN) Is Achieving High Returns On Its Capital

Should You Investigate Cross Country Healthcare, Inc. (NASDAQ:CCRN) At US$23.23?

Sep 13
Should You Investigate Cross Country Healthcare, Inc. (NASDAQ:CCRN) At US$23.23?

These 4 Measures Indicate That Cross Country Healthcare (NASDAQ:CCRN) Is Using Debt Reasonably Well

Aug 19
These 4 Measures Indicate That Cross Country Healthcare (NASDAQ:CCRN) Is Using Debt Reasonably Well

Returns on Capital Paint A Bright Future For Cross Country Healthcare (NASDAQ:CCRN)

Jun 26
Returns on Capital Paint A Bright Future For Cross Country Healthcare (NASDAQ:CCRN)

At US$27.39, Is It Time To Put Cross Country Healthcare, Inc. (NASDAQ:CCRN) On Your Watch List?

Jun 08
At US$27.39, Is It Time To Put Cross Country Healthcare, Inc. (NASDAQ:CCRN) On Your Watch List?

Is Cross Country Healthcare (NASDAQ:CCRN) Using Too Much Debt?

Apr 28
Is Cross Country Healthcare (NASDAQ:CCRN) Using Too Much Debt?

Returns on Capital Paint A Bright Future For Cross Country Healthcare (NASDAQ:CCRN)

Mar 15
Returns on Capital Paint A Bright Future For Cross Country Healthcare (NASDAQ:CCRN)

Why Cross Country Healthcare, Inc. (NASDAQ:CCRN) Could Be Worth Watching

Mar 02
Why Cross Country Healthcare, Inc. (NASDAQ:CCRN) Could Be Worth Watching

If EPS Growth Is Important To You, Cross Country Healthcare (NASDAQ:CCRN) Presents An Opportunity

Jan 20
If EPS Growth Is Important To You, Cross Country Healthcare (NASDAQ:CCRN) Presents An Opportunity

Cross Country Healthcare (NASDAQ:CCRN) Has A Rock Solid Balance Sheet

Jan 05
Cross Country Healthcare (NASDAQ:CCRN) Has A Rock Solid Balance Sheet

Is Now The Time To Look At Buying Cross Country Healthcare, Inc. (NASDAQ:CCRN)?

Oct 29
Is Now The Time To Look At Buying Cross Country Healthcare, Inc. (NASDAQ:CCRN)?

Investors Shouldn't Overlook Cross Country Healthcare's (NASDAQ:CCRN) Impressive Returns On Capital

Oct 14
Investors Shouldn't Overlook Cross Country Healthcare's (NASDAQ:CCRN) Impressive Returns On Capital

Paring My Cross Country Healthcare Gains

Sep 29

Should You Be Adding Cross Country Healthcare (NASDAQ:CCRN) To Your Watchlist Today?

Sep 26
Should You Be Adding Cross Country Healthcare (NASDAQ:CCRN) To Your Watchlist Today?

Cross Country Healthcare to acquire assets of Mint Medical Physician Staffing, LP and Lotus Medical Staffing LLC

Sep 14

Cross Country Healthcare (NASDAQ:CCRN) Has A Pretty Healthy Balance Sheet

Aug 21
Cross Country Healthcare (NASDAQ:CCRN) Has A Pretty Healthy Balance Sheet

Cross Country Healthcare rises postmarket on $100M stock buyback program

Aug 16

Cross Country Healthcare Q2 Non-GAAP EPS, revenue beats, Q3 guidance provided

Aug 03

Is Cross Country Healthcare, Inc. (NASDAQ:CCRN) Potentially Undervalued?

Jun 16
Is Cross Country Healthcare, Inc. (NASDAQ:CCRN) Potentially Undervalued?

Buying Back In To Cross Country Healthcare

May 17

Is Cross Country Healthcare (NASDAQ:CCRN) Using Too Much Debt?

May 11
Is Cross Country Healthcare (NASDAQ:CCRN) Using Too Much Debt?

Earnings and Revenue Growth Forecasts

NasdaqGS:CCRN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,49851N/AN/A2
12/31/20251,4083359679
12/31/20241,3852065739
3/31/20241,77646195208N/A
12/31/20232,02073235248N/A
9/30/20232,234102228241N/A
6/30/20232,428124298311N/A
3/31/20232,641156200210N/A
12/31/20222,807188125134N/A
9/30/20222,8192274756N/A
6/30/20222,558216-95-87N/A
3/31/20222,136175-98-90N/A
12/31/20211,677132-93-86N/A
9/30/20211,25259-16-10N/A
6/30/20211,07134-21-16N/A
3/31/20219569-20-15N/A
12/31/2020836-132327N/A
9/30/2020836-191520N/A
6/30/2020851-211014N/A
3/31/2020837-58710N/A
12/31/2019822-5836N/A
9/30/2019808-76710N/A
6/30/2019800-742428N/A
3/31/2019801-201621N/A
12/31/2018816-171621N/A
9/30/2018835313439N/A
6/30/2018863383438N/A
3/31/2018868415257N/A
12/31/201786538N/A46N/A
9/30/20178682N/A27N/A
6/30/20178549N/A43N/A
3/31/2017845-13N/A29N/A
12/31/20168348N/A30N/A
9/30/201680410N/A32N/A
6/30/20167851N/A25N/A
3/31/201677821N/A21N/A
12/31/20157674N/A18N/A
9/30/2015762-10N/A18N/A
6/30/2015756-22N/A7N/A
3/31/2015686-28N/A5N/A
12/31/2014618-32N/A-4N/A
9/30/2014539-64N/A-6N/A
6/30/2014458-55N/A-1N/A
3/31/2014446-54N/A1N/A
12/31/2013438-54N/A9N/A
9/30/2013441-4N/A16N/A
6/30/2013445-5N/A11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CCRN's earnings are forecast to decline over the next 3 years (-3.6% per year).

Earnings vs Market: CCRN's earnings are forecast to decline over the next 3 years (-3.6% per year).

High Growth Earnings: CCRN's earnings are forecast to decline over the next 3 years.

Revenue vs Market: CCRN's revenue is expected to decline over the next 3 years (-9% per year).

High Growth Revenue: CCRN's revenue is forecast to decline over the next 3 years (-9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CCRN's Return on Equity is forecast to be low in 3 years time (4.7%).


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.